PPARγ mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome

Journal of Nutrition

Volumn 138, Issue 5, 2008, Pages 903-907

  Macias Gonzalez, Manuel ^a,b   Cardona, Fernando ^a,b   Queipo Ortuño, Maribel ^b   Bernal, Rosa ^a,b   Martin, Miguel ^a,b   Tinahones, Francisco J ^a,c  

^a Instituto de Salud Carlos III   (Spain)

^b Hospital University Carlos Haya de Málaga   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ALANINE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; FAT INTAKE; FEMALE; GENE SEQUENCE; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MONONUCLEAR CELL; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY MASS; CHEMISTRY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; INSULIN RESISTANCE; LIPID PEROXIDATION; POLYMERASE CHAIN REACTION; PROTEIN CARBONYLATION;

ALANINE; BODY MASS INDEX; DIETARY FATS; GENE EXPRESSION; GLUTATHIONE; HUMANS; INSULIN RESISTANCE; LEUKOCYTES, MONONUCLEAR; LIPID PEROXIDATION; METABOLIC SYNDROME X; NF-KAPPA B; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; PROTEIN CARBONYLATION; RNA, MESSENGER; TRIGLYCERIDES;

EID: 42449116898     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/138.5.903     Document Type: Article

References (36)

1. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, et al.; European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364-72.
2. Lehrke M, Lazar MA. The many faces of PPARγ. Cell. 2005;123:993-9.
3. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
4. Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D, Buckwalter S, Ledbetter JA, Clar EA. Characterization of human inducible costimulator ligand expression and function. J Immunol. 2000;164:4689-96.
5. Setoguchi K, Misaki Y, Terauchi Y, Yamauchi T, Kawahata K, Kadowaki T, Yamamoto K. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B-cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest. 2001;108:1667-75.
6. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka TM. Proinflammatory stimulation and pioglitazone treatment regulate PPARγ levels in PBMCs from healthy controls and multiple sclerosis patients. J Immunol. 2005;175:4948-55.
7. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA. 2000;97:4844-9.
8. Sharma AM, Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007;92:386-95.
9. Vaccaro O, Mancini FP, Ruffa G, Sabatino L, Iovine C, Masulli M, Colantuoni V, Riccardi G. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene in healthy individuals. Clin Endocrinol (Oxf). 2002;57:481-6.
10. Julien P, Vohl MC, Gaudet D, Gagné C, Lévesque G, Després JP, Cadelis F, Brun LD, Nadeau A, Ven Murthy MR. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes. 1997;46:2063-8.
11. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-48.
12. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARγ in humans. Mol Genet Metab. 2004;83:93-102.
13. Soriguer F, Morcillo S, Cardona F, Rojo-Martinez G, Almaraz MC, Ruiz de Adana MS, Olveira G, Tinahones F, Esteva I. Pro12Ala polymorphism of the PPARγ2 is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr. 2006;136:2325-30.
14. Cardona F, Morcilo S, Gonzalo-Marin M, Garrido-Sanchez L, Macias-Gonzalez M, Tinahones FJ. Pro12Ala sequence variant of the PPARγ gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin Chem. 2006;52:1920-5.
15. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341-55.
16. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16:125-32.
17. Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost. 2006;4:1003-10.
18. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J. 2005;81:1-6.
19. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-12.
20. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.
21. Saxena R, Madhu SV, Shukla R, Prabhu KM, Gambhir JK. Postprandial hypertriglyceridemia and oxidative stress in patients of type 2 diabetes mellitus with macrovascular complications. Clin Chim Acta. 2005;359:101-8.
22. Cardona F, Tunez I, Tasset I, Garrido-Sanchez L, Collantes E, Tinahones FJ. Circulating antioxidant defences are decreased in healthy people after a high fat meal. Br J Nutr. 2008;99:44-8.
23. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004;110:1564-71.
24. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-95.
25. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464-78.
26. Flohé L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114-21.
27. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6.
28. Serrano A, del Arco I, Pavon FJ, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008;54:226-34.
29. Queipo-Ortuño M, de Dios Colmenero J, Macias M, Bravo MJ, Morata P. Preparation of bacterial DNA template by boiling and effect of immunoglobulin G as an inhibitor in real-time PCR for serum samples from patients with brucellosis. Clin Vaccine Immun. 2008;15:293-6.
30. Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. Nucl Recept. 2007;25:1.
31. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47:142-56.
32. Rosenson RS, Wolff DA, Huskin AL, Helenowski JB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30:1945-51.
33. Lu B, Moser AH, Shigenaga JK, Feingold KR, Grunfeld C. Repression of type II nuclear hormone receptors, receptor CoA and their target genes in adipose tissues during the acute-phase response. J Lipid Res. 2006;47:2179-90.
34. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, et al. PPARγ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007;3:634-47.
35. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 2006;10:389-406.
36. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med. 2003;9:169-76.